BIOCORP CORPORATE | EUR36 vs. EUR33 Forecasting solid sales growth for Mallya and strong commitment from pharmaceutical partners
º We are expecting big ramp up of Mallya sales over the next two yearsRecurrent high single-digit milestones in the next two years
We re-iterate BUY and increases our TP to EUR36 vs EUR33
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.